|
1
|
Gao YX, Yang TW, Yin JM, Yang PX, Kou BX,
Chai MY, Liu XN and Chen DX: Progress and prospects of biomarkers
in primary liver cancer (Review). Int J Oncol. 57:54–66.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen W, Chiang CL and Dawson LA: Efficacy
and safety of radiotherapy for primary liver cancer. Chin Clin
Oncol. 10(9)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Velázquez RF, Rodríguez M, Navascués CA,
Linares A, Pérez R, Sotorríos NG, Martínez I and Rodrigo L:
Prospective analysis of risk factors for hepatocellular carcinoma
in patients with liver cirrhosis. Hepatology. 37:520–527.
2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide:Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Alisi A and Balsano C: Enhancing the
efficacy of hepatocellular carcinoma chemotherapeutics with natural
anticancer agents. Nutr Rev. 65 (12 Pt 1):550–553. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Han K and Kim JH: Transarterial
chemoembolization in hepatocellular carcinoma treatment: Barcelona
clinic liver cancer staging system. World J Gastroenterol.
21:10327–10335. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Raoul JL, Forner A, Bolondi L, Cheung TT,
Kloeckner R and de Baere T: Updated use of TACE for hepatocellular
carcinoma treatment: How and when to use it based on clinical
evidence. Cancer Treat Rev. 72:28–36. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee SW, Peng YC, Lien HC, Ko CW, Tung CF
and Chang CS: Clinical values of Barcelona Clinic Liver Cancer
subgroup and up-to-7 criteria in intermediate stage hepatocellular
carcinoma with transcatheter arterial chemoembolization. World J
Clin Cases. 10:7275–7284. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kotsifa E, Vergadis C, Vailas M, Machairas
N, Kykalos S, Damaskos C, Garmpis N, Lianos GD and Schizas D:
Transarterial chemoembolization for hepatocellular carcinoma: Why,
when, how? J Pers Med. 12(436)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Samman BS, Hussein A, Samman RS and
Alharbi AS: Common sensitive diagnostic and prognostic markers in
hepatocellular carcinoma and their clinical significance: A review.
Cureus. 14(e23952)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pinato DJ, Arizumi T, Jang JW, Allara E,
Suppiah PI, Smirne C, Tait P, Pai M, Grossi G, Kim YW, et al:
Combined sequential use of HAP and ART scores to predict survival
outcome and treatment failure following chemoembolization in
hepatocellular carcinoma: A multi-center comparative study.
Oncotarget. 7:44705–44718. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Op den Winkel M, Nagel D, Op den Winkel P,
Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P,
Göhring P, et al: Transarterial chemoembolization for
hepatocellular carcinoma: development and external validation of
the Munich-TACE score. Eur J Gastroenterol Hepatol. 30:44–53.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ruf A, Dirchwolf M and Freeman RB: From
Child-Pugh to MELD score and beyond: Taking a walk down memory
lane. Ann Hepatol. 27(100535)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ,
Guo RP, Lin XJ and Lau WY: Prognostic nomogram for patients with
unresectable hepatocellular carcinoma after transcatheter arterial
chemoembolization. J Hepatol. 63:122–130. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mähringer-Kunz A, Weinmann A, Schmidtmann
I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C,
Galle PR and Kloeckner R: Validation of the SNACOR clinical scoring
system after transarterial chemoembolisation in patients with
hepatocellular carcinoma. BMC Cancer. 18(489)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kadalayil L, Benini R, Pallan L, O'Beirne
J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, et
al: A simple prognostic scoring system for patients receiving
transarterial embolisation for hepatocellular cancer. Ann Oncol.
24:2565–2570. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang JB, Chen Y, Zhang B, Xie X, Zhang L,
Ge N, Ren Z and Ye SL: Prognostic significance of serum
gamma-glutamyl transferase in patients with intermediate
hepatocellular carcinoma treated with transcatheter arterial
chemoembolization. Eur J Gastroenterol Hepatol. 23:787–793.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xuan ZD, Zhou L, Wang Y and Zheng X:
Prognostic value of the combination of serum levels of vascular
endothelial growth factor, C-reactive protein and contrast-enhanced
ultrasound in patients with primary liver cancer who underwent
transcatheter arterial chemoembolization. Expert Rev Anticancer
Ther. 17:1169–1178. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yuan C, Yuan M, Chen M, Ouyang J, Tan W,
Dai F, Yang D, Liu S, Zheng Y, Zhou C and Cheng Y: Prognostic
implication of a novel metabolism-related gene signature in
hepatocellular carcinoma. Front Oncol. 11(666199)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rahimi-Dehkordi N, Nourijelyani K,
Nasiri-Tousi M, Ghodssi-Ghassemabadi R, Azmoudeh-Ardalan F and
Nedjat S: Model for End stage Liver Disease (MELD) and
Child-Turcotte-Pugh (CTP) scores: Ability to predict mortality and
removal from liver transplantation waiting list due to poor medical
conditions. Arch Iran Med. 17:118–121. 2014.PubMed/NCBI
|
|
21
|
Peng Y, Qi X and Guo X: Child-Pugh versus
MELD score for the assessment of prognosis in liver cirrhosis:A
systematic review and meta-analysis of observational studies.
Medicine (Baltimore). 95(e2877)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang W, Knovich MA, Coffman LG, Torti FM
and Torti SV: Serum ferritin: Past, present and future. Biochim
Biophys Acta. 1800:760–769. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Plays M, Müller S and Rodriguez R:
Chemistry and biology of ferritin. Metallomics.
13(mfab021)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Guo Q, Li L, Hou S, Yuan Z, Li C, Zhang W,
Zheng L and Li X: The role of iron in cancer progression. Front
Oncol. 11(778492)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Facciorusso A, Del Prete V, Antonino M,
Neve V, Crucinio N, Di Leo A, Carr BI and Barone M: Serum ferritin
as a new prognostic factor in hepatocellular carcinoma patients
treated with radiofrequency ablation. J Gastroenterol Hepatol.
29:1905–1910. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wu SJ, Zhang ZZ, Cheng NS, Xiong XZ and
Yang L: Preoperative serum ferritin is an independent prognostic
factor for liver cancer after hepatectomy. Surg Oncol. 29:159–167.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ghanaati H and Mohammadifard M and
Mohammadifard M: A review of applying transarterial
chemoembolization (TACE) method for management of hepatocellular
carcinoma. J Family Med Prim Care. 10:3553–3560. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Manjunatha N, Ganduri V, Rajasekaran K,
Duraiyarasan S and Adefuye M: Transarterial chemoembolization and
unresectable hepatocellular carcinoma: A narrative review. Cureus.
14(e28439)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chung SW, Park MK, Cho YY, Park Y, Lee CH,
Oh H, Jang H, Kim MA, Kim SW, Nam JY, et al: Effectiveness of
transarterial chemoembolization-first treatment for advanced
hepatocellular carcinoma: A propensity score matching analysis. J
Hepatocell Carcinoma. 8:587–598. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Alkhateeb AA and Connor JR: The
significance of ferritin in cancer: Anti-oxidation, inflammation
and tumorigenesis. Biochim Biophys Acta. 1836:245–254.
2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nielsen P, Günther U, Dürken M, Fischer R
and Düllmann J: Serum ferritin iron in iron overload and liver
damage: Correlation to body iron stores and diagnostic relevance. J
Lab Clin Med. 135:413–418. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: diagnostic and therapeutic guidelines for
hemophagocytic lymphohisti-ocytosis. Pediatr Blood Cancer.
48:124–131. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kalantar-Zadeh K and Lee GH: The
fascinating but deceptive ferritin: To measure it or not to measure
it in chronic kidney disease? Clin J Am Soc Nephrol. 1 (Suppl
1):S9–S18. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang X, Fang X, Zheng W, Zhou J, Song Z,
Xu M, Min J and Wang F: Genetic support of a causal relationship
between iron status and type 2 diabetes: A mendelian randomization
study. J Clin Endocrinol Metab. 106:e4641–e4651. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Suárez-Ortegón MF, Ensaldo-Carrasco E, Shi
T, McLachlan S, Fernández-Real JM and Wild SH: Ferritin, metabolic
syndrome and its components: A systematic review and meta-analysis.
Atherosclerosis. 275:97–106. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jia J, Wang M, Meng J, Ma Y, Wang Y, Miao
N, Teng J, Zhu D, Shi H, Sun Y, et al: Ferritin triggers neutrophil
extracellular trap-mediated cytokine storm through Msr1
contributing to adult-onset Still's disease pathogenesis. Nat
Commun. 13(6804)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee S, Song A and Eo W: Serum ferritin as
a prognostic biomarker for survival in relapsed or refractory
metastatic colorectal cancer. J Cancer. 7:957–964. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Guo G, Sun M, Li Y, Yang W, Wang X, Yu Z,
Li C, Hui Y, Fan X, Jiang K and Sun C: Serum ferritin has limited
prognostic value on mortality risk in patients with decompensated
cirrhosis: A propensity score matching analysis. Lab Med. 54:47–55.
2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Facciorusso A, Di Maso M and Muscatiello
N: Drug-eluting beads versus conventional chemoembolization for the
treatment of unresectable hepatocellular carcinoma: A
meta-analysis. Dig Liver Dis. 48:571–577. 2016.PubMed/NCBI View Article : Google Scholar
|
